Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio's Approved Drugs Database

Rebetol

Ribavirin

Download PDF containing detailed information. PDF Version

Image Results

Press Releases About Rebetol:
Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients	1st November, 2008		BASEL, Switzerland, November 1 /PRNewswire/ -- Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS(R)
Biotech Tracker news - Maxim Continues to Gain Back Lost Ground	1st May, 2001	Biotracker	Maxim Continues to Gain Back Lost Ground October 21,
Biotech Tracker News - FDA Committee Will Review Pegasys - Copegus	1st January, 1970	Biotracker	Biotech Tracker News - FDA Committee Will Review Pegasys - Copegus Combination
Chronic hepatitis B and C: a chronic lack of effective treatment	1st January, 1970	Datamonitor	Chronic hepatitis B / C: a chronic lack of effective treatment The World Health Organization estimates that one-third of the entire world's population has been exposed to hepatitis B (HBV)

This page has been viewed 26 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Rebetol across BioPortfolio, or for Rebetol Research Reports

Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

BioPortfolio's Approved Drugs Database

Rebetol

Ribavirin

Image Results

Press Releases About Rebetol: